TVGN News & Events

Tevogen received written notice from the Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market, the company announced. "With compliance restored, Tevogen continues to advance its evolution into a diversified, fully integrated healthcare enterprise, combining immunotherapy, artificial intelligence, and disciplined capital allocation to drive long-term value. The company's strategic direction includes evaluating targeted acquisition opportunities that complement its core platforms. These initiatives are part of a broader effort to transition toward a cash-flow-positive operating model while maintaining a strong commitment to affordability and efficiency," the company said.

Tevogen announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Over the past year, the company has built a proprietary database of more than 655M peptide sequences derived from approximately 24M proteins, representing nearly 16B data points across multiple disease areas. This database is continuously enriched using analysis of 37M scientific publications. In recent beta testing of its PredicTcell model, Tevogen reported: Recall improved from 87% to 92%; Precision improved from 40% to 48%; Higher overall accuracy scores; Increased true positives and reduced missed targets, and; Dramatically expanded training sample size. These results allow the model to improve in identifying which immune targets are likely to succeed. The current version, trained on 1.8M data points, is nearly 20 times more robust than the initial model, reflecting rapid scale and learning acceleration, the company said.

Tevogen announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50M. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek Stobinski; Generics: Sadiq Khan and David Banko; Contract Research: William Keane; Biotech: Lori Grosso; Artificial Intelligence: Mittul Mehta.

Dr. Ryan Saadi, Founder & CEO Tevogen, sent the following letter to shareholders: "Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives. Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time. Based on preliminary evaluations, the combined entities under consideration may generate aggregate annual revenues in excess of $50 million. While these discussions remain subject to customary due diligence, negotiation, and definitive agreements, we believe the opportunity aligns with our disciplined growth strategy. Tevogen was built on the belief that innovation and affordability are not mutually exclusive. As we expand, we remain committed to disciplined capital allocation, operational efficiency, and long-term shareholder value creation. We appreciate your continued trust and support as we pursue strategic initiatives intended to strengthen Tevogen's financial foundation while advancing our mission of developing accessible immunotherapies."